Oak Hill Bio Obtain Global Rights for Rugonersen

In June 2023, Roche announced they would not be moving forward with a clinical trial for rugonersen, an investigational ASO for AS, and would be looking for an external partner to take over the development. 

Oak Hill Bio has entered into an exclusive license agreement with Roche to obtain the global rights for a phase 3-ready, potential best-in-class treatment for individuals with Angelman Syndrome. 

Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics.   

Read the community letter and FAQs.

Read the press release.